Thursday, October 21, 2021
اُردُو نیوز Newspaper Live-TV(UK) Live-TV(PK)
اُردُو نیوز Newspaper
Live-TV(UK) Live-TV(PK)

Cyclacel's leukemia drug for elderly patients fails in key study

Cyclacel's leukemia drug for elderly patients fails in key study
February 23, 2017
NEW JERSEY - Cyclacel Pharmaceuticals Inc said its lead experimental drug did not help elderly patients with acute myeloid leukemia live longer in a late-stage study. The drug developer's stock was down about 19 percent in light premarket trading on Thursday. The treatment, sapacitabine, was tested on patients aged 70 years or more who are not candidates for chemotherapy or have refused it, Cyclacel said. An improvement in remission rates - a secondary goal - was there for patients who had discontinued therapy at the time of analysis, the company added. Cyclacel said it was going to reevaluate its continued investment in sapacitabine for blood cancer. -Reuters
تازہ ترین خبریں حاصل کرنے کے لیے فوری اطلاع کی اجازت دیں

آپ کسی بھی وقت دائیں طرف نیچے بیل آئیکن پر صرف ایک کلک کے ذریعے آسانی سے سبسکرائب کر سکتے ہیں۔